Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Trial Profile

Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms Correlate
  • Sponsors Bayer
  • Most Recent Events

    • 04 Nov 2019 Results (n=1037) assessing safety and effectiveness of in patients with metastatic colorectal cancer published in the European Journal of Cancer
    • 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
    • 16 Jan 2019 According to Bayer media release, data will be presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top